BioVaxys Technology Corp.
BIOV
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 205.50% | 73.11% | 145.21% | -6.33% | -40.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.62% | 79.85% | 122.99% | -8.67% | -50.77% |
| Operating Income | -214.62% | -79.85% | -122.99% | 8.67% | 50.77% |
| Income Before Tax | -296.27% | -12.90% | 59.08% | 63.65% | 154.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -296.27% | -12.90% | 59.08% | 63.65% | 154.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -296.27% | -12.90% | 59.08% | 63.65% | 154.10% |
| EBIT | -214.62% | -79.85% | -122.99% | 8.67% | 50.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -211.54% | 32.52% | 72.92% | 77.38% | 141.94% |
| Normalized Basic EPS | -75.00% | 9.68% | 84.43% | 52.00% | 69.23% |
| EPS Diluted | -211.54% | 32.52% | 72.92% | 77.38% | 141.94% |
| Normalized Diluted EPS | -75.00% | 9.68% | 84.43% | 52.00% | 69.23% |
| Average Basic Shares Outstanding | 80.52% | 67.02% | 49.90% | 59.58% | 27.39% |
| Average Diluted Shares Outstanding | 80.52% | 67.02% | 49.90% | 59.58% | 27.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |